MPPP, also known as 4-propionyloxy-4-phenyl-N-methylpiperidine and 3-desmethylprodine, has a systematic name of (1-methyl-4-phenylpiperidin-4-yl) propanoate.
Warning: Last items in stock!
MPPP, also known as 4-propionyloxy-4-phenyl-N-methylpiperidine and 3-desmethylprodine, has a systematic name of (1-methyl-4-phenylpiperidin-4-yl) propanoate. It is a Schedule I drug. MPPP has a CAS number of 13147-09-6, a PubChem Identifier of CID 61583, a DrugBank Identifier of DB01478, a ChemSpider Identifier of 55493, and a ChEMBL of 279865. Its formula is C15H21NO2. MPPP has a composition of 77.21 percent Carbon, 9.93 percent Hydrogen, 6 percent Nitrogen, and 6.86 percent Oxygen. There is an atom count of 40, a bond count of 41, and a cyclomatic number of 2. There is a chain atom count of 5, a chain bond count of 6, an asymmetric atom count of zero, and a rotatable bond count of 4. MPPP has a polar surface area of 12.47. Developed by Hoffman-La Roche in the 1940's, it was synthesized for recreational drug use by a 23-yr old named Barry Kidston in 1977. 1-Methyl-4-phenyl-4-propionoxypiperidine was a reversal of the ester of pethidine, a meperidine skeleton that was once legal. Barry Kidston studied the Albert Ziering papers of 1947 to be able to synthesize the drug into its recreational state. Kidston also came up with a major impurity by using an elevated temperature when the reaction was not suppose to rise about 30 Celsius. This impurity, MPTP, caused him to have Parkinson's Disease-like symptoms after trying the drug. MPTP can cause these symptoms, which are irreversible. When synthesizing MPPP one must make sure to keep temperatures under this guideline or toxic impurities can develop.